Healthcare provider profile · identity verified

Mark C Antonishen, M.D.

Internal Medicine · BOYNE CITY, MI · NPI 1518971654

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	672	177
Lisinopril	Lisinopril	455	117
Levothyroxine Sodium	Levothyroxine Sodium	344	85
Omeprazole	Omeprazole	341	93
Amlodipine Besylate	Amlodipine Besylate	329	86
Metoprolol Succinate	Metoprolol Succinate	288	71
Metformin Hcl	Metformin Hcl	218	60
Losartan Potassium	Losartan Potassium	192	54
Simvastatin	Simvastatin	182	49
Hydrochlorothiazide	Hydrochlorothiazide	179	49
Eliquis	Apixaban	154	33
Sertraline Hcl	Sertraline Hcl	139	31
Gabapentin	Gabapentin	137	32
Furosemide	Furosemide	131	34
Citalopram Hbr	Citalopram Hydrobromide	124	26
Rosuvastatin Calcium	Rosuvastatin Calcium	124	36
Clopidogrel	Clopidogrel Bisulfate	121	29
Carvedilol	Carvedilol	114	31
Tamsulosin Hcl	Tamsulosin Hcl	113	39
Trazodone Hcl	Trazodone Hcl	113	32
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	102	19
Potassium Chloride	Potassium Chloride	99	31
Famotidine	Famotidine	81	13
Metoprolol Tartrate	Metoprolol Tartrate	81	21
Allopurinol	Allopurinol	79	20
Glipizide	Glipizide	77	15
Albuterol Sulfate Hfa	Albuterol Sulfate	71	30
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	71	19
Atenolol	Atenolol	70	19
Montelukast Sodium	Montelukast Sodium	69	16
Pantoprazole Sodium	Pantoprazole Sodium	68	18
Meloxicam	Meloxicam	67	17
Duloxetine Hcl	Duloxetine Hcl	66	19
Pioglitazone Hcl	Pioglitazone Hcl	64	17
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	62	14
Spironolactone	Spironolactone	59	15
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	55	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	52	13
Xarelto	Rivaroxaban	52	11
Tramadol Hcl	Tramadol Hcl	49	15
Finasteride	Finasteride	47	14
Entresto	Sacubitril/Valsartan	46	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	46	suppressed
Fluticasone Propionate	Fluticasone Propionate	45	19
Warfarin Sodium	Warfarin Sodium	43	11
Escitalopram Oxalate	Escitalopram Oxalate	41	15
Olmesartan Medoxomil	Olmesartan Medoxomil	41	suppressed
Alprazolam	Alprazolam	40	18
Donepezil Hcl	Donepezil Hcl	39	14
Esomeprazole Magnesium	Esomeprazole Magnesium	39	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	37	suppressed
Ventolin Hfa	Albuterol Sulfate	32	suppressed
Ezetimibe	Ezetimibe	31	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	31	suppressed
Bupropion Hcl Sr	Bupropion Hcl	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Benazepril Hcl	Benazepril Hcl	28	suppressed
Humalog Kwikpen U-100	Insulin Lispro	28	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Ramipril	Ramipril	28	suppressed
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Oxycodone Hcl	Oxycodone Hcl	26	suppressed
Symbicort	Budesonide/Formoterol Fumarate	26	suppressed
Glipizide Er	Glipizide	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Estradiol	Estradiol	24	suppressed
Lansoprazole	Lansoprazole	24	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	19
Mirtazapine	Mirtazapine	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	21
Ibuprofen	Ibuprofen	22	suppressed
Valsartan	Valsartan	22	suppressed
Azithromycin	Azithromycin	21	17
Bumetanide	Bumetanide	21	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Prednisone	Prednisone	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Synthroid	Levothyroxine Sodium	20	suppressed
Valacyclovir	Valacyclovir Hcl	19	13
Flecainide Acetate	Flecainide Acetate	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Glimepiride	Glimepiride	17	suppressed
Propranolol Hcl Er	Propranolol Hcl	17	suppressed
Lorazepam	Lorazepam	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Irbesartan	Irbesartan	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Adderall	Dextroamphetamine/Amphetamine	13	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Metformin Er Osmotic	Metformin Hcl	13	suppressed
Praluent Pen	Alirocumab	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	12	suppressed
Hydroxyurea	Hydroxyurea	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Ozempic	Semaglutide	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Dutasteride	Dutasteride	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Nystatin	Nystatin	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error